The Montelukast Intermediate Market share is estimated to 4,794.763 thousand USD by 2023 and Expected to register CAGR of 4.34% During the Forecast Period.

The Global Montelukast Intermediate Market has been evaluated as a moderately growing market, and it is expected that the market will continue to grow similarly in the near future. Montelukast is a leukotriene receptor antagonist (LTRA) used to prevent wheezing, difficulty in breathing, chest tightness, and coughing caused by asthma.

Top Market Players

Recent Study of Market Research Future recognizes the following companies are the major Industry Growth Drivers in the global Montelukast Intermediate market that includes Lonza, Merck KGaA, Oxford BioMedica, Spark Therapeutics, Inc., FinVector Vision Therapies, Novasep, FUJIFILM Diosynth Biotechnologies U.S.A., Inc, Brammer Bio and uniQure N.V.

Request for a free Sample Here: https://www.marketresearchfuture.com/sample_request/7887

Montelukast Intermediate Market Dynamics

Factors characterizing the Montelukast Intermediate market growth are worldwide rising prevalence of asthma, bronchospasm, allergic rhinitis, and urticaria, burgeoning pharmaceutical industry coupled with the increasing demand from API manufacturers, and montelukast patent expiration along with the increasing presence of generics. In 2016, asthma ranked twenty third (global) and thirty-first (in low- and middle-income countries — LMICs) among the leading causes of premature mortality (YLL). The World Health Organization (WHO) has estimated that 15 million disability-adjusted life-years are lost and 250,000 asthma deaths are reported worldwide every year.

Montelukast Intermediate Market Therapeutics and Clinical Assessment by Application (Asthma, Allergic Rhinitis, Bronchospasm and Urticaria), Regional Scope, Industry Size, Growth, Major Players and Trend Analysis – Global Forecast till 2023.

Major Key Findings of the Montelukast Intermediate Market Study:

Global Montelukast Intermediate Market is projected to reach over 4,794.763 Thousand by 2023 with 34% CAGR during the review period of 2018-2023.

Americas accounted for the largest share due to the rising prevalence of asthma and allergic rhinitis in the US and Canada and increasing research and development activities related to the pharmaceutical intermediates.

Asthma segment by application is projected to value 65 thousand in 2023.

4 Market Dynamics

4.1 Introduction

4.2 Drivers

4.2.1 Worldwide Rising Prevalence Of Asthma, Bronchospasm, Allergic Rhinitis, And Urticaria

4.2.2 Burgeoning Pharmaceutical Industry Coupled With The Growing Demand From API Manufacturers

4.2.3 Montelukast Patent Expiration Along With The Increasing Presence Of Generics 22

4.3 Restraints

4.3.1 Presence Of Stringent Regulatory Policies

4.3.2 High Cost Of Manufacturing Building Blocks For APIs

4.4 Opportunity

4.4.1 Ongoing Research And Development Activities

5 Market Factor Analysis

5.1 Value Chain Analysis

5.1.1 Raw Material Sourcing

5.1.2 Manufacturing

5.1.3 Distribution & Sales

5.1.4 End Users

5.2 Porter’s Five Forces Model

5.2.1 Threat Of New Entrants

5.2.2 Bargaining Power Of Suppliers

5.2.3 Bargaining Power Of Buyers

5.2.4 Threat Of Substitutes

5.2.5 Intensity Of Rivalry

5.3 Investment Opportunities

5.4 Pricing Analysis

5.5 Clinical Trials

5.5.1 Overview

5.6 Patent Analysis

5.7 Regulatory Scenario

Browse Complete Premium Report Details @ https://www.marketresearchfuture.com/reports/montelukast-intermediate-market-7887

6 Global Montelukast Intermediate Market, By Application

6.1 Overview

6.2 Asthma

6.3 Allergic Rhinitis

6.4 Bronchospasm

6.5 Urticaria

Geographically, the global montelukast intermediate market has been divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.

North America is expected to dominate the market. The market growth in this region is mainly due to the presence of giant pharmaceutical companies and sophisticated healthcare infrastructure and the rising prevalence of asthma and allergic rhinitis in the US and Canada

The poor air quality due to high fuel emission is increasing the incidence of asthma, allergy, and chronic obstructive pulmonary disease (COPD) in the UK, Germany, and France. The European Respiratory Society reported that, currently, about 30 Million children and adults less than 45 years old have asthma within the UK and Ireland have some of the highest rates of asthma in the world. In Germany, there are an estimated 4 Million asthmatics.

Get an Exclusive Discount@ https://www.marketresearchfuture.com/check-discount/7887

In APAC, According to the WHO, currently, there are about 3 million asthmatics in Japan of whom 7% have severe, and 30% have moderate asthma. In Australia, one child out of six under the age of 16 is affected by asthma, while, India has an estimated 15 to 20 Million asthmatics population. Currently, the prevalence of asthma is between 10% and 15% in 5 to 11-year-old children in India. In October 2018, more than 25% of the total population of India was sensitized with different forms of allergens and suffered from atopic rhinitis, bronchial asthma, urticaria, dermatitis, oral and gastrointestinal symptoms, ocular allergy, and life-threatening anaphylaxis.

The Middle East and Africa market is projected to hold the least share in the global montelukast intermediate market. In this region, the Middle East is anticipated to dominate owing to the presence of countries such as Egypt, Saudi Arabia, and other.

Contact:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com